O. Holgado, C. Callol, J.M. Virto, I. Ibarbia et al. Validation of an Automated Screening Platform in Zebrafish (2009). Screening Europe 2009.

C. Callol-Massot, A. Muriana, A. Cruz, i. Ibarbia, A. Letamendia, J.C. Ispizua- Belmonte (2006). Generation of Zebrafish Models for Cardiovascular Diseases: HTS application. High Throughput Screening San Francisco, 2006.

C. Callol-Massot, A. Muriana, A. Letamendia, A. Cruz (2008). Generation of Zebrafish Models for Cardiovascular Diseases. Screening America 2008.

M. A. Pardo, S. Rainieri, A. Muriana, C. Callol et al. (2009).DARENET: a novel technology platform to promote the use of zebrafish model. International Zebrafish Congress Rome 2009.

Olaia Holgado, Juan Maria Virto, Izaskun Ibarbia, Patrice Dubreuil, Didier Pez, Ainhoa Letamendia, Martine Humbert, Alain Moussy, Carles Callol-Massot.

The zebrafish embryos have recently gained relevance in biomedical research thanks to some of its characteristics including embryo transparency, small size, ease of manipulation and possibility to evaluate different internal organs avoiding invasive methodologies. Combined with the possibility to adapt the model with an automatic device and the reduced cost associated to each assay, the model is an ideal killer experiment in early phases of drug discovery as well as a novel method to increase the selection arguments to reduce the candidates to enter into the Drug Development processes.

Cardiotoxicity is one of the most important reasons for drug attrition during the process of Drug Development. Evaluation of cardiotoxicity and especially HERG channel inhibition is described in regulatory guidelines, but limitations demands the development of new complementary assays that can also evaluate the heart function from a holistic point of view. Biobide has set up a novel in vivo automated platform that allows testing compounds in zebrafish embryos.

To evaluate and validate the quality of the analysis system, the model and the value of the information, we have used a panel of blind-coded Tyrosine kinase inhibitors that had been previously described in other in vitro and in vivo assays. The results indicate that our automated method provides with high informative and complementary data that can significantly improve the process of selection of new candidates with low or no cardiotoxicity

E. Luño, O. Holgado, a. Muriana, A. Letamendia, C. Callol-Massot (2009). Automated Analysis of Cardiotoxicity in Zebrafish. CHI World Pharmaceutical Congress 2009.